Association of Anticholinergic burden with adverse effects in older people with Intellectual Disabilities in Ireland: An observational cross-sectional study
![Thumbnail](/xmlui/themes/Mirage2/images/white_rectangle.jpeg)
File Type:
PDFItem Type:
Journal ArticleDate:
2016Access:
openAccessCitation:
O'Dwyer, M., Maidment, I., Bennett, K., Peklar, J., Mulryan, N., McCallion P., McCarron, M., Henman, M, Association of Anticholinergic burden with adverse effects in older people with Intellectual Disabilities in Ireland: An observational cross-sectional study, British Journal of Psychiatry, 209, 2016, 504 - 510Download Item:
Abstract:
Background:Older people with intellectual disabilities (ID) receive anticholinergic drugs but no studies to date have investigated cumulative anticholinergic exposure and its effects in adults with ID.
Aim: To determine the cumulative exposure to anticholinergics and the factors associated with high exposure.
Methods A modified Anticholinergic Cognitive Burden scale (ACB) was calculated for a representative cohort of 736 people over 40 years with intellectual disabilities, and associations with demographic and clinical factors assessed.
Results Age over 65 years was associated with higher exposure (ACB 1-4- OR 3·28; 95% CI 1·49-7·28, ACB 5+- OR 3·08; 95% CI 1·20-7·63), as was a mental health condition (ACB 1-4- OR 9·79; 95% CI 5·63-17·02, ACB 5+- OR 23·74; 95% CI 12·29-45·83). Day time drowsiness was associated with higher ACB (p<0·001) and chronic constipation reported more frequently (26·6% ACB 5+ vs 7·5% ACB 0) (p<0·001).
Conclusions Older people with intellectual disabilities and with mental health conditions were exposed to high anticholinergic burden. This was associated with daytime dozing and constipation.
Author's Homepage:
http://people.tcd.ie/mccarrmhttp://people.tcd.ie/modwyer6
http://people.tcd.ie/mhenman
Description:
PUBLISHEDType of material:
Journal ArticleSeries/Report no:
British Journal of Psychiatry209
Availability:
Full text availableKeywords:
anticholinergic (AC) activitySubject (TCD):
Ageing , Inclusive Society , ADVERSE DRUG REACTIONS , Ageing & Intellectual Disability Issues , Ageing, Health and Intellectual Disability , CLINICAL OUTCOMES , Clinical Pharmacy , Drug utilisation and epidemiology , GERIATRIC PSYCHIATRY , Gerontology and geriatrics , HEALTH SERVICES RESEARCH , Mental health and intellectual disability , PHARMACOEPIDEMIOLOGY , Patient safety , Public Health , SEVERE INTELLECTUAL DISABILITY , THERAPEUTICS , health outcomes researchDOI:
http://dx.doi.org/10.1192/bjp.bp.115.173971Metadata
Show full item recordLicences: